Latest News & Features
Americas
Goldfinch Bio, a US company focused on developing treatments for kidney disease, has agreed to license a cannabinoid receptor 1 antibody from Japanese pharmaceutical manufacturer Takeda. 4 October 2019
Big Pharma
Novartis has teamed with Microsoft to launch a new artificial intelligence innovation lab, which it says has the potential to “transform” and “reimagine” medicine. 3 October 2019
Americas
The US Patent and Trademark Office (USPTO) has granted a new CRISPR-Cas9 patent to the University of California (UC), the University of Vienna and Emmanuelle Charpentier, marking the fifth consecutive week that the USPTO has approved a new patent in their CRISPR portfolio. 3 October 2019
Americas
Canadian pharmaceutical company Bausch Health is suing Sandoz for patent infringement over its notice of intent to release a generic version of Xifaxan, Bausch’s irritable bowel syndrome drug. 3 October 2019
Americas
Evolve BioSystems and the University of California have jointly sued Abbott Laboratories for patent infringement over a soon-to-be-launched probiotic product. 3 October 2019
Big Pharma
The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines. 1 October 2019
Genetics
As all sides prepare for a milestone case in the battle over rights to CRISPR/Cas9, LSIPR’s Rory O’Neill finds the CEO of ERS Genomics in a positive mood. 1 October 2019
Big Pharma
As lawyers and industry prepare for a possible no-deal Brexit, the uncertainty surrounding its impact is palpable, as LSIPR’s Saman Javed discovers. 1 October 2019
Big Pharma
LSIPR’s Sarah Morgan investigates the current state of play of M&A in the sector and predicts the next year of activity. 30 September 2019
Biotechnology
In-house counsel face daily challenges when managing and maintaining their IP portfolios. LSIPR asked two in-house counsel for the biggest challenges they face when managing and maintaining their IP portfolios. Here are the five things we learned. 30 September 2019